No Detail Found!

Neoadjuvant Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer

Author(s)
Chongxiang Xue Beijing University of Chinese Medicine,Beijing,China
Huijing Dong Beijing University of Chinese Medicine,Beijing,China
Ying Chen Beijing University of Chinese Medicine,Beijing,China
Xingyu Lu Beijing University of Chinese Medicine,Beijing,China
Shuyue Zheng Department of Clinical Oncology, Li Ka Shing Faculty of Medicine, The University of Hong Kong,Hong Kong,China
Huijuan Cui Department of Integrative Oncology, National Centre for Respiratory Medicine, China-Japan Friendship Hospital,Chaoyang District,China
Abstract
Lung cancer is the leading cause of cancer-related death worldwide.A meta-analysis was conducted to assess the bene ts and risks of neoadjuvant immune checkpoint inhibitors (ICIs) in non-small cell lung cancer (NSCLC).Online databases, including PubMed, Embase, Web of Science, Cochrane Library, and clinicaltrials.gov, were retrospectively and systematically searched for eligible trials from database inception to May 2021. A total of 792 patients from 21 clinical trials were included. For surgical data, the pooled operation rate and R0 resection rate were 92% (95% CI 87-96%) and 97% (95% CI 94-99%). Additionally, neoadjuvant ICIs achieved a major pathological response (MPR) of 39% (95% CI 25-53%), including 25% (95% CI 16-36%) pathological complete response (pCR). With radiological response assessment, the pooled objective response rate (ORR) and disease control rate (DCR) were 44% (95% CI 21-68%) and 88% (95% CI 75-98%), respectively.In terms of safety, the pooled rate of any-grade and grade 3 5 treatment-related adverse e ects (TRAEs) were 57% (95% CI 38-76%) and 15% (95% CI 6-28%). Eventually, the study concludes that neoadjuvant ICIs are e ective and safe for patients with early-stage NSCLC.
Publication Details
Page(s) 779-788
DOI DOI not available
Published Journal: Journal of College of Physicians and Surgeons--Pakistan : JCPSP, Volume: 32, Issue: 6, Year: 2022

Request the full text from PASTIC

Keywords
Meta-analysis, Non-small Cell Lung Cancer, Neoadjuvant therapy, Immune checkpoint inhibitors
0

Citations

0

Downloads

147

Views